The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B

BACKGROUND: Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half‐life (EHL) products in Canada during 2016 to 2018. OBJECTIVES: To evaluate if patient‐reported outcome measures (PROMs) improved in Canadian persons with hemophilia who switched from standard half‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Haowei (Linda), Yang, Ming, Poon, Man‐Chiu, Lee, Adrienne, Robinson, K. Sue, Sholzberg, Michelle, Wu, John, Iorio, Alfonso, Blanchette, Victor, Carcao, Manuel, Klaassen, Robert J., Jackson, Shannon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505988/
https://www.ncbi.nlm.nih.gov/pubmed/34667922
http://dx.doi.org/10.1002/rth2.12601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505988/
https://www.ncbi.nlm.nih.gov/pubmed/34667922
http://dx.doi.org/10.1002/rth2.12601

Ejemplares similares